MSCs for Prevention of MI-induced HF

PHASE3CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

November 1, 2024

Study Completion Date

November 1, 2024

Conditions
Myocardial Infarction, AcuteMyocardial Infarction FirstMyocardial Infarction, Anterior WallCardiac Remodeling, VentricularSTEMIRegenerative MedicineHeart Failure
Interventions
BIOLOGICAL

Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs)

cGMP grade WJ-MSCs. 10\^7 WJ-MSCs will be delivered through the intracoronary route. WJ-MSCs will be infused at a rate of 2.5 ml/min across three portions.

OTHER

Conventional Treatment

Beta-blocker, angiotensin-converting enzyme (ACE) inhibitor, aldosterone antagonist, aspirin, ticagrelor, statin, and glyceryl trinitrate plus cardiac rehabilitation.

Trial Locations (3)

Unknown

Al-Zahra Heart Hospital, Shiraz University of Medical Sciences, Shiraz

Faghihi Hospital, Shiraz

Namazee Hospital, Shiraz

All Listed Sponsors
collaborator

National Institute of Medical Research Development (NIMAD), Iran

UNKNOWN

lead

Shiraz University of Medical Sciences

OTHER

NCT05043610 - MSCs for Prevention of MI-induced HF | Biotech Hunter | Biotech Hunter